Genedrive MT-RNR1 ID Kit to detect genetic variation and protect hearing in babies: early value appraisal.
The Genedrive MT-RNR1 ID Kit has potential benefits in identifying babies at risk of hearing loss from aminoglycoside due to the MT-RNR1 m.1555A>G variant, allowing for alternative antibiotics to be used instead. However, managing the risk of early access is important, including ensuring timely antibiotics, avoiding unnecessary use of alternative antibiotics, and confirming positive results. The economic evidence suggests cost-effectiveness, but upfront costs may be high. Data should be generated in centers with babies from different ethnicities to promote equality.
Recent Posts
Advancing Participatory Arts Health in Dutch Care Systems
Participatory arts health is gaining recognition as a valuable complement to traditional medical care, supporting both physical and psychosocial well-being for people living with chronic conditions and those at the end of life. In this article we explore how creative, participatory approaches ...
Advancing Tarlatamab for Small Cell Lung Cancer Treatment
New Treatment Option for Relapsed Extensive-Stage Small Cell Lung Cancer
Tarlatamab small cell lung therapy has received a positive opinion from the European Medicines Agency (EMA) for marketing authorisation. The bispecific T-cell engager is recommended as monotherapy ...
FDA Approves Once-Weekly Basal Insulin Awiqli® for Type 2 Diabetes Management
The US Food and Drug Administration (FDA) has approved Awiqli® (insulin icodec-abae) as the once-weekly basal insulin for adults with type 2 diabetes. This approval marks a major advancement in reducing treatment burden by decreasing basal insulin injections from seven to one per week.